CareDx Awarded CE Mark for AlloSeq HCT in Hematopoietic Cell Transplantation

CareDx has received CE marking for its AlloSeq HCT chimerism testing kit and AlloSeq HCT interpretation software for patients who have received hematopoietic cell transplantation (HCT).

The next-generation sequencing test evaluates the success of a hematopoietic stem cell transplant by measuring the relative ratio of the recipient and the donor cell population post-transplantation.

The test is designed to overcome the limitations of current chimerism testing, which rely on the detection and quantification of short, repeated sequences of DNA to evaluate donor cell engraftment. Individuals with two different sets of DNA are called human chimeras.

South San Francisco, Calif.-based CareDx specializes in the discovery, development and commercialization of healthcare solutions for transplant patients and caregivers.